SCHEMBL163288

SCHEMBL163288

O=C(c1ccc(F)cc1)c1cc2ccccc2c(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
ALOX5 P09917 1/20 0.43
ALDH1A1 P00352 2/20 0.42
CNR2 P34972 1/20 0.42
GRM2 Q14416 2/20 0.41
LTA4H P09960 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HSD17B14 Q9BPX1 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164886 0.78 ALDH1A1 (0.55) NPC1TSHRMAPK1KDM4EMEN1
SCHEMBL30023908 0.76 KDM4E (0.50) TSHRKDM4EMEN1KMT2AALDH1A1
SCHEMBL1990776 0.76 KDM4E (0.50) TSHRKDM4EMEN1KMT2AALDH1A1
SCHEMBL3128329 0.74 TRPM8 (0.48) NPC1TSHRMAPK1KDM4EMEN1
SCHEMBL159829 0.73 KDM4E (0.53) TSHRMAPK1KDM4EMEN1HTT
SCHEMBL21166298 0.72 LTA4H (0.44) NPC1TSHRMAPK1MEN1KMT2A
SCHEMBL113126 0.72 LTA4H (0.44) NPC1TSHRMAPK1CNR2LTA4H
SCHEMBL3281702 0.71 KDM4E (0.50) NPC1TSHRMAPK1KDM4EMEN1
SCHEMBL7258823 0.70 CYP19A1 (0.47) NPC1MAPK1KDM4EMEN1HTT
SCHEMBL10627250 0.70 HSD17B14 (0.49) NPC1TSHRMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2663553-B1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS AMBIT BIOSCIENCES CORP (US) 2015-08-26 EP disclosed
EP-2663553-A2 QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-11-20 EP disclosed
US-20130296363-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS AMBIT BIOSCIENCES CORPORATION (US) 2013-11-07 US disclosed
WO-2012030944-A2 QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296363-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS JAK3, JAK2, JAK1 NPC1 3491/4885TSHR 2529/4885MAPK1 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.